Regulation

  • Specialism

  • Lifecycle Stage

GNMA 10: Policy and public affairs for life science companies

GNMA 9: Supranational HTAs

GNL 39: Changes to data exclusivity

GNMA 8: Market access for medtech, diagnostics and digital technologies in the UK

GNL37: UK experimental use exemptions

GNMA 7: Impact of Brexit on the regulatory approval process for medicines in the UK

GNL 36: Placing medical devices on the UK market after the end of Brexit transition

GNL 35: What the UK-EU Trade and Cooperation Agreement means for pharma and medical device companies

GNMA 6: Impact of conditional approval and approval under exceptional circumstances on national pricing and reimbursement

GNMA 5: Learning from previous NICE consultations

GNMA 4: Cell and Gene Therapies – innovative contracting trends in Europe

GNMA 3: How can early access schemes support accelerated patient access in Europe?

GNL 26: Biosimilars explained

GNMA 2: Top five reasons why products fail to achieve a positive NICE recommendation

GNMA 1: Improving access to orphan medicines

GNL 30: Regulating life sciences products in the transition period

GNL 25: Data and market exclusivity: additional protections

GNL 21: Licensing manufacturers, wholesale dealers and brokers

GNL 24: Data and market exclusivity: what it is and how long it lasts

GNL 20: Paediatric extensions

GNL 19: Pre-clinical, clinical and post-market surveillance

GNL 14: Medical Devices Regulation – The New Rules

GNL 13: Medical Devices Regulation – The Current Rules

GNL 12: Regulations on Medicine, Advertising and Promotion

GNL 11: Marketing Authorisation for Medicines – Types, Length and Revocation

Sign-Up For Free

Sign-up to receive up-to-date information and advice on tax developments within your industry.

Sign-up for free